Minzasolmin
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Minzasolmin
- Molecular weight
- 425.6
- Structure (SMILES)
- CCCC[C@H](Cc1c[nH]c2ccccc12)NC(=O)c1cnc(N2CCN(C)CC2)s1
- dlx 313
- DLX-313
- dlx313
- DLX313
- minzasolmin
- Minzasolmin
- Minzasolmin (UCB0599)
- minzasolmin [INN]
- MINZASOLMIN [USAN]
- Minzasolmin [WHO-DD]
- minzasolmin inn
- minzasolmin ucb0599
- minzasolmin usan
- minzasolmin who dd
- minzasolmina
- Minzasolmina
- minzasolmine
- Minzasolmine
- ucb 0599
- UCB-0599
- ucb0599
- Ucb0599
- UCB0599
- CAS registry numbers
- 1802518-92-8
- ChEMBL ID
- CHEMBL5095072
- InChIKey
- GDFWCSZNQVAQGR-GOSISDBHSA-N
- PubChem compound IDs
- 118279413
- FDA ingredient codes (UNII)
- 3N0435TG2D
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -solmin
Investigated indications
- Condition
- Parkinson Disease
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005180
- Subject identifier
- D010300
Open Targets indications
- Condition identifier
- MONDO_0005180
- Highest recorded phase
- 2
- NCT04658186
- NCT04875962
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 2
- Polar surface area
- 64.26
- Calculated partition coefficient (ALogP)
- 3.91
- Calculated partition coefficient (XLogP)
- 4.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 8
- Heavy atoms
- 30
- Molecular formula
- C23H31N5OS
- Monoisotopic mass
- 425.22493180
- Natural product
- No
- Recorded assays
- 1
- Active assays
- 1
Active assay types
- Confirmatory
Related records
Trials (5)
- A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
- A Study to Assess the Bioavailability of a New Tablet Formulation of Minzasolmin and the Effect of Food in Healthy Participants
- A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B
- A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)
- An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease
In development for (1)
- Parkinson disease Phase 2